
    
      This is a study with two parallel treatment groups where subjects are randomized to receive
      RMC-035 or a matching placebo in a double-blind fashion. The study will comprise of a
      screening visit, followed by CABG and/or valve replacement on Day 1, double-blind treatment
      period and a follow-up period up to Day 30.
    
  